Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRX NASDAQ:HOOK NASDAQ:PYRGF NASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$3.09$3.26$1.50▼$3.87$40.13M0.836,682 shsN/AHOOKHOOKIPA Pharma$0.91-2.8%$1.02$0.72▼$5.30$11.09M0.93121,796 shs7,265 shsPYRGFPyroGenesis Canada$0.21-0.3%$0.29$0.21▼$0.71$38.46M0.8313,165 shs851 shsRENBRenovaro$0.24-6.1%$0.28$0.22▼$2.10$40.96M0.54833,617 shs720,559 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%-3.13%-16.26%+62.63%-40.58%HOOKHOOKIPA Pharma0.00%+4.60%+1.90%-41.85%-82.40%PYRGFPyroGenesis Canada0.00%-8.48%-28.31%-47.96%-64.65%RENBRenovaro0.00%-0.42%-6.85%-23.23%-64.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEGRXEagle Pharmaceuticals1.654 of 5 stars0.02.00.03.90.03.30.0HOOKHOOKIPA Pharma3.3271 of 5 stars3.25.00.00.03.22.50.6PYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AN/AN/AN/ARENBRenovaro1.1656 of 5 stars0.05.00.00.01.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50394.51% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ARENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.16$7.73 per share0.40N/A∞HOOKHOOKIPA Pharma$9.35M1.19N/AN/A$4.25 per share0.21PYRGFPyroGenesis Canada$9.14M4.21N/AN/A($0.01) per share-20.51RENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AHOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%11/12/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ARENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AHOOKHOOKIPA PharmaN/A3.613.61PYRGFPyroGenesis CanadaN/A0.600.50RENBRenovaroN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%HOOKHOOKIPA Pharma63.88%PYRGFPyroGenesis Canada0.03%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%HOOKHOOKIPA Pharma3.30%PYRGFPyroGenesis Canada47.68%RENBRenovaro0.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionablePYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataRENBRenovaro20172.12 million171.26 millionOptionableHOOK, EGRX, RENB, and PYRGF HeadlinesRecent News About These CompaniesRenovaro BioSciences to change corporate name to ‘Lunai Bioworks’August 28 at 7:49 PM | msn.comRenovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced DiagnosticsAugust 27, 2025 | accessnewswire.comARenovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense RisksAugust 8, 2025 | accessnewswire.comARenovaro Biosciences Granted Nasdaq Compliance ExtensionAugust 6, 2025 | tipranks.comAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksJuly 30, 2025 | tmcnet.comRenovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI SectorJuly 28, 2025 | accessnewswire.comARenovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | finanznachrichten.dePeer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | accessnewswire.comARenovaro Biosciences Receives Nasdaq Compliance NoticeJuly 14, 2025 | tipranks.comRenovaro Strengthens Balance Sheet Through Debt ... - MorningstarJuly 11, 2025 | morningstar.comMRenovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesJuly 9, 2025 | accessnewswire.comARenovaro Biosciences Restructures Debt with Exchange AgreementJuly 9, 2025 | tipranks.comRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - NasdaqJuly 2, 2025 | nasdaq.comRenovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security NeedsJune 30, 2025 | accessnewswire.comARenovaro subsidiary secures patent for drug discovery AIJune 5, 2025 | uk.investing.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingenJune 5, 2025 | nl.investing.comRenovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and DiagnosticsJune 5, 2025 | msn.comRENB stock touches 52-week low at $0.27 amid market challengesJune 5, 2025 | investing.comRenovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkelingJune 3, 2025 | nl.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOOK, EGRX, RENB, and PYRGF Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$3.09 0.00 (0.00%) As of 08/29/2025Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.HOOKIPA Pharma NASDAQ:HOOK$0.91 -0.03 (-2.77%) As of 08/29/2025 03:28 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.PyroGenesis Canada NASDAQ:PYRGF$0.21 0.00 (-0.29%) As of 08/29/2025 11:49 AM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Renovaro NASDAQ:RENB$0.24 -0.02 (-6.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.24 +0.00 (+1.68%) As of 08/29/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
